Next-Generation and Third-Generation Sequencing of Lung Cancer Biomarkers

Abstract

In lung cancer, biomarker-guided therapy selection has greatly improved patient outcome. The recent introduction of next-generation sequencing (NGS) technology has rapidly expanded our understanding of disease-driving gene mutations and resulted in identification of key lung cancer biomarkers. In addition to identifying new biomarkers, NGS has also significantly improved lung cancer biomarker diagnostic testing. Currently, NGS provides a single assay/approach capable of both rapid lung biomarker mutation detection and simultaneous screening of multiple biomarkers utilizing minimal disease tissue. This chapter will explore the background and methodology of NGS-based lung cancer biomarker testing along with the barriers to adoption of NGS-based clinical testing.